Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A.
Mavrakanas
Nikolaos
N
Mendrinos
Efstratios
E
Pournaras
Constantin J
CJ
Salzmann
Joel
J
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005584:Fovea Centralis / Q000098:blood supply*; D006801:Humans; D056965:Injections, Intraocular; D008875:Middle Aged; D000069579:Ranibizumab; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000209:etiology*; D013684:Telangiectasis / Q000145:classification / Q000150:complications*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab